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Mutations in the gene encoding the enzyme tafazzin, TAZ, cause Barth syndrome
(BTHS). Individuals with this X-linked multisystem disorder present cardiomyopathy
(CM) (often dilated), skeletal muscle weakness, neutropenia, growth retardation,
and 3-methylglutaconic aciduria. Biopsies of the heart, liver and skeletal muscle
of patients have revealed mitochondrial malformations and dysfunctions. It is the
purpose of this review to summarize recent results of studies on various animal or
cell models of Barth syndrome, which have characterized biochemically the strong
cellular defects associated with TAZ mutations. Tafazzin is a mitochondrial phospholipid-
lysophospholipid transacylase that shuttles acyl groups between phospholipids and
regulates the remodeling of cardiolipin (CL), a unique inner mitochondrial membrane
phospholipid dimer consisting of two phosphatidyl residues linked by a glycerol bridge.
After their biosynthesis, the acyl chains of CLs may be modified in remodeling processes
involving up to three different enzymes. Their characteristic acyl chain composition
depends on the function of tafazzin, although the enzyme itself surprisingly lacks
acyl specificity. CLs are crucial for correct mitochondrial structure and function. In
addition to their function in the basic mitochondrial function of ATP production, CLs
play essential roles in cardiac function, apoptosis, autophagy, cell cycle regulation
and Fe-S cluster biosynthesis. Recent developments in tafazzin research have
provided strong insights into the link between mitochondrial dysfunction and the
production of reactive oxygen species (ROS). An important tool has been the
generation of BTHS-specific induced pluripotent stem cells (iPSCs) from BTHS patients.
In a complementary approach, disease-specific mutations have been introduced
into wild-type iPSC lines enabling direct comparison with isogenic controls. iPSC-
derived cardiomyocytes were then characterized using biochemical and classical
bioenergetic approaches. The cells are tested in a “heart-on-chip” assay to model the
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pathophysiology in vitro, to characterize the underlying mechanism of BTHS deriving
from TAZ mutations, mitochondrial deficiencies and ROS production and leading to
tissue defects, and to evaluate potential therapies with the use of mitochondrially
targeted antioxidants.
Keywords: barth syndrome, tafazzin, cardiolipin, mitochondria, stem cells, cellular models, mitochondrially
targeted antioxidant
INTRODUCTION
Given the importance of cardiolipin (CL) for mitochondrial
oxidative function and its role in many signaling pathways, it
is not surprising that changes in CL biosynthesis are associated
with a number of pathological conditions (Claypool and Koehler,
2012; Mejia et al., 2014a; Ren et al., 2014). Decreases in CL
per se and decrease in CL content linked to changes in its acyl
chain composition and/or CL peroxidation have been associated
with a disruption of mitochondrial homeostasis in multiple
tissues in diverse pathological conditions, including ischemia,
hypothyroidism, aging (Shi et al., 2010), heart failure, ischemic
reperfusion injury, and neurodegenerative disease (Chicco and
Sparagna, 2007; Claypool and Koehler, 2012; Lu and Claypool,
2015). At the cellular level, CLs can promote membrane fusion
processes critical for normal mitochondrial dynamics acting as
a non-bilayer forming lipid (with calcium ions) and capable
of aﬀecting the function and activities of autophagic proteins
(Chu et al., 2014). CLs have been implicated in mitophagy,
the removal of damaged mitochondria, which is a critical
step in mitochondrial quality control (Zhu et al., 2013). The
accumulation of damaged mitochondria resulting from defective
elimination by mitophagy is linked to deﬁcient mitochondrial
respiration and high levels of reactive oxygen species (ROS;
Gandhi et al., 2009). CLs have also been implicated in apoptotic
signaling and the crosstalk between mitochondria and the
vacuole (Zischka et al., 2008). Finally, mitochondria can sense
signals linked to changes in energy demand and respond to them
by aﬀecting nuclear gene expression possibly through changes in
CL levels and acyl chain length (Jahnke et al., 2009).
In this review, we focus on the Barth Syndrome (BTHS), an
X-linked disease which is characterized by CL deﬁciency and
alteration of CL species as a result of mutation of the Tafazzin
(TAZ) gene (Barth et al., 1981, 1983). We focus on recent
progress in the ﬁeld, dealing with the elucidation of tafazzin
function and localization, CL synthesis and remodeling, multiple
models of BTHS and recent developments achieved with induced
pluripotent stem cells (iPSCs) from the tissues of patients with
tafazzin gene mutations characteristically associated with BTHS,
together with “heart-on-chip” technology.
Throughout this review we will cite studies on the model
organism, baker’s yeast. The Saccharomyces cerevisiae taz1 gene
(YPR140w) is homologous to the human TAZ gene and highly
conserved and the studies have had a considerable inﬂuence on
our understanding of BTHS. Even more important has been
the generation of human model systems: The diﬀerentiation
of disease-relevant and patient-speciﬁc cell lines into relevant
cell types have made it possible to generate unlimited amounts
of appropriate cellular material for biochemical studies and
mechanical measurements. However, for useful insight to
be obtained with these tools, appropriate cell-based assays
reproducing crucial aspects of the disease studied are required.
For example, studies aiming to elucidate the link between
aberrant ROS levels in mitochondria and defects in sarcomere
organization and mechanical capacities have been driven by the
development of cardiac muscle-derived human pluripotent stem
cells and “heart-on-chip” technology.
THE BARTH SYNDROME
In a brief preliminary communication, Barth et al. (1981)
described a family with a “new” X-linked syndrome aﬀecting
heart muscle, skeletal muscle and neutrophils. Barth et al.
(1983), a large Dutch kindred was described with CM, skeletal
myopathy and neutropenia, and with high infant mortality due
to infection or cardiac failure. BTHS is considered to be a rare
X-linked genetic disease characterized by CM, skeletal myopathy,
growth retardation, neutropenia, and abnormally high levels of
3-methylglutaconic acid excretion in urine (Barth et al., 1983,
1999; Kelley et al., 1991; Spencer et al., 2006; Clarke et al., 2013)
(Table 1). The authors also suggested that a similar disorder
described by Neustein et al. (1979) as “an X-linked recessive
CM with abnormal mitochondria” might be the same syndrome.
Neustein et al. (1979) had reported that “A transvascular
endomyocardial biopsy from an infant with CM and chronic
congestive heart failure showed abnormal mitochondria when
examined by electron microscopy. At necropsy, similar abnormal
mitochondria were seen in skeletal muscles, liver, and kidney”.
The ultrastructure of the aﬀected tissues clearly suggested a
mitochondrial disease (Barth et al., 1981).
Mutations in the gene TAZ, encoding the phospholipid–
lysophospholipid transacylase, cause BTHS (Bione et al., 1996;
Barth et al., 2004). BTHS may be fatal if not diagnosed and
treated early (Barth et al., 1983; Kelley et al., 1991; Johnston
et al., 1997). 3-Methylglutaconic aciduria (MGA) is observed in a
heterogeneous group of syndromes. It results from an increase in
the excretion of 3-methylglutaconic and 3-methylglutaric acids,
both of which are breakdown products of leucine catabolism
(Wysocki and Hahnel, 1976).
BTHS generally presents as a CM aﬀecting male individuals,
often in infancy (Figure 1), although a case of BTHSwas reported
recently in a female patient as well (Cosson et al., 2012). Multiple
additional abnormalities may be observed, including ventricular
arrhythmia, sudden cardiac death, prolonged Q-Tc interval (the
QT interval is an indicator of the electrical depolarization
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TABLE 1 | Clinical features of Barth syndrome (common features are
indicated by an asterisk∗ and the most prominent ones are shown in red).
Cardiovascular ∗Dilated cardiomyopathy
∗Left ventricular non-compaction
Prolonged corrected QT interval
Endocardial fibroelastosis
Ventricular arrhythmia/Sudden cardiac death
Undulating cardiomyopathy
Hypertrophic cardiomyopathy (rarely)
Neuromuscular ∗Delayed motor milestones
∗Proximal myopathy
∗Abnormal fatigability
∗Exercise intolerance
Neurological ∗Mild learning disabilities
∗Attention deficits
Strokes (cardiac embolic)
Hematological and Infectious ∗Neutropenia
∗Recurrent mouth ulcers and sore gums
∗Perianal dermatitis
Recurrent bacterial infections
Septicemia
Endocrine and Metabolic ∗3-Methylglutaconic aciduria
∗Constitutional growth retardation
with delayed bone age
∗Delayed puberty
Hypocholesterolemia
Hypoglycemia
Lactic acidosis (often accompanies cardiac failure)
Osteopenia
Gastrointestinal ∗Oromotor feeding problems
Episodic or chronic diarrhea
Dysmorphicfeatures ∗Deep-set eyes
∗Full cheeks
∗Prominent ears (older boys)
Fetal Cardiomyopathy
Fetal hydrops
Miscarriage and stillbirth of male fetuses
Modified from Clarke et al. (2013).
and repolarization of the ventricle), delayed motor milestones,
proximal myopathy, lethargy, and fatigue, exercise intolerance,
neutropenia (absent to severe; persistent, intermittent, or
perfectly cyclic), compensatory monocytosis, recurrent bacterial
infection, hypoglycemia, lactic acidosis, growth, and pubertal
delay, feeding problems (poor appetite), failure to thrive, episodic
diarrhea, characteristic facies, and an X-linked family history
(Ichida et al., 2001; Steward et al., 2010).
Biopsies of the heart, liver, and skeletal muscles of patients
reveal the presence of malformed mitochondria, with tightly
stacked or circular bundles of cristae (Barth et al., 1983; Hodgson
et al., 1987; Orstavik et al., 1998; Bissler et al., 2002). The
mitochondria of lymphoblasts from patients havemuch less inner
membrane than normal mitochondria, with collapsed cristae and
a high frequency of fragmentation (Xu et al., 2005; Acehan et al.,
2007; Gonzalvez et al., 2008, 2013). Similar abnormalities have
been observed in HeLa-TAZ mutants (Gonzalvez et al., 2013)
(Figure 2).
Cardiomyopathy is a Major Feature of BTHS
Cardiomyopathy is the major clinical feature of BTHS, with a
high incidence in early life. Prenatal losses or morbidity may also
result from fetal CM (Steward et al., 2010). Patients may present
dilated or hypertrophic CM, endomyocardial ﬁbroelastosis,
and/or a developmental CM known as myocardial non-
compaction (left ventricular) or hypertrabeculation (“spongy
myocardium”) (Figure 1) (Spencer et al., 2006; Clarke et al.,
2013). It is usually of the dilated type and may be accompanied
by endocardial ﬁbroelastosis (Ades et al., 1993). During
the development of dilated CM, cardiac myocytes undergo
remodeling, including elongation, and death, whereas cardiac
ﬁbroblasts proliferate and their collagen secretion increases.
Myocardial ﬁbrosis has been reported in patients with BTHS
(Neustein et al., 1979; Marziliano et al., 2007). About 50%
of patients have prominent left ventricular trabeculations,
suggestive of a form of left ventricular non-compaction (LVNC).
Left ventricular abnormalities may be remodeled with age.
There may also be a transition between relatively dilated
and hypertrophic morphologies, sometimes referred to as an
“undulating” phenotype, in children with LVNC (Pignatelli et al.,
2003; Hanke et al., 2012). There is also a risk of ventricular
arrhythmia and sudden death in BTHS, and this risk appears
to be independent of CM severity (Ades et al., 1993; Barth
et al., 2004; Yen et al., 2008). Spencer et al. (2006) found
that 13% of patients had documented ventricular arrhythmia
requiring deﬁbrillator implantation (Roberts et al., 2012). BTHS
patients may also suﬀer sudden cardiac death, as illustrated by
the instances of sudden cardiac death in the family histories
of two BTHS patients with documented arrhythmias (Spencer
et al., 2005). Prolonged or borderline prolonged Q-Tc interval
(the usual Q-Tc interval, the repolarization time between two
heart beats, is ≤440 ms) is found in a high proportion of
BTHS patients (43%), although this did not appear to be
correlated with documented episodes of ventricular arrhythmia.
A longer Q-Tc interval is associated with a higher risk of
“torsade de pointes”, and borderline prolonged long Q-Tc
intervals have been found in children with hypertrophic CM
and dilated CM due to other causes, potentially reﬂecting
the underlying cardiac muscle abnormalities, which include
myoﬁbrillar disorganization in BTHS (Spencer et al., 2006). CM
is a common clinical presentation of mitochondrial diseases, and
mitochondrial dysfunction has been identiﬁed as the probable
cause of the CM observed in BTHS (Merante et al., 1994; Bunse
et al., 2003; Sproule and Kaufmann, 2008). Clarke and coworkers
(Clarke et al., 2013) recommended systematic screening for
BTHS in male neonates, babies and young boys with dilated
cardiomyopathy (DCM) or left LVNC (Figure 1), and in males
with unexplained ventricular arrhythmia or sudden death family
history.
TAFAZZIN INTRODUCED BRIEFLY
The causal gene of BTHS, TAZ, encodes tafazzin (TAZ, G4.5,
OMIM 300394) and was ﬁrst discovered as the genetic origin of
Barth syndrome Bione et al. (1996). The group responsible for
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FIGURE 1 | Left ventricular non-compaction (LVNC) associated with a dilated cardiomyopathy phenotype in Barth syndrome (BTHS) patient.
(A) Example of a normal heart and a heart with dilated CM associated with LVNC. (B) BTHS patient with LVNC associated with dilated CM. Echocardiogram (apical
4-chamber view) of patient with BTHS depicting LVNC with associated DCM phenotype. The scale relates to Doppler effect velocity. Note the deep left ventricular
trabeculations and dilated left ventricular chamber (Jefferies, 2013, with the permission of the editor, Wiley-Blackwell, John Wiley & Sons, USA).
identifying the tafazzin gene named it after a comic masochistic
character (“tafazzi”) from an Italian television sports show.
The tafazzin gene/protein has certainly lived up to its name
(Houtkooper et al., 2009).
Tafazzin is a ubiquitous mitochondrial enzyme responsible for
speciﬁc remodeling of the CLs by catalyzing acyl transfer from a
phospholipid to a lysophospholipid. Since changes in CL amount
and composition is central to the eﬀect of tafazzin, it is necessary
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FIGURE 2 | Electron micrographs of mitochondria with an abnormal
appearance in BTHS dilated cardiomyopathy and of lymphoblasts
from a patient with Barth syndrome. (A) Higher power electron
micrograph. The mitochondria are enlarged and crowded together, with many
touching each another. The cristae are not parallel, but are stacked, and many
are organized into abnormal circular arrays (white big arrows). The nucleus (N)
is centrally placed, but the myofilaments, with their cross-striations (small
white arrows), are displaced to the periphery of the cell. Lamellar bodies are
also dispersed within the cytoplasm. One autophagolysosome is also
detectable (large black arrow; AutoPh.) [reprinted with the permission of Sarah
Clarke et al. (2013) and BiomedCentral]. (B) Control lymphoblasts.
(C,D) Structure of mitochondria from control lymphoblasts. (E) Lymphoblasts
from a patient. (F,G) Structure of mitochondria from the lymphoblasts of a
patient. Size bars are ∗Electron-translucent areas surrounded by the outer
mitochondrial membrane (or a membrane derived from it). [from Dr. Patrice X.
Petit, unpublished data and (Gonzalvez et al., 2013)].
to ﬁrst take a detailed look at the biosynthesis of CL and its role
in the mitochondria before we can discuss the eﬀect of tafazzin
function and tafazzin mutations on cellular biochemistry and
physiology.
CARDIOLIPIN
Decades of successful studies on the structural roles of
lipids in membranes have resulted in the elucidation of the
pathways by which these compounds are biosynthesized and
the complex networks by which they are regulated. Until very
recently, mitochondrial phospholipids attracted less attention.
However, the identiﬁcation of mitochondria as organelles
involved not only in bioenergetic functions, but also in multiple
regulatory and coordinating tasks, has focused research eﬀorts
on phospholipid signaling within and outside mitochondria
especially in connection with apoptosis, autophagy and cell
cycle regulation. These new insights are also linked to a greater
awareness of the importance of the physical properties of the
membrane for membrane function, including ﬂuidity, defects,
lateral mobility, and curvature strain (Kagan et al., 2014).
Mitochondrial membranes have a lower phospholipid-
to-protein ratio than other organelle membranes, a high
phosphatidylcholine (PC) and phosphatidylethanolamine (PE)
content (together accounting for 80% of the total phosphorus
present), low levels of sterols and sphingolipids, and a
strong enrichment of a single phospholipid, CL (Horvath
and Daum, 2013). The major polyglycerophospholipid in
mammalian tissues is bis-(1,2-diacyl-sn-glycero-3-phospho)-1′ -
3′-sn-glycerol, or CL. CL was ﬁrst isolated from beef heart
(Pangborn, 1942), and its biosynthesis in mammals was ﬁrst
described in rat liver (Hostetler et al., 1971). It is found
predominantly in the inner, and, to a lesser extent, outer
membranes of mitochondria in non-pathological situations
(Ardail et al., 1990; Hovius et al., 1990, 1993), and it is particularly
abundant in the so-called “mitochondrial contact sites (MCSs)”
in which the outer and inner membranes come into contact
(Nicolay et al., 1990). MCSs have diverse functions in the
regulation of apoptosis, organelle dynamics, cellular traﬃcking,
and the immune response (Nicolay et al., 1990).
Cardiolipin has several original properties, including a speciﬁc
chemical structure, with four acyl chains displaying highly
speciﬁc sensitivity to Ca2+, which can induce an inverted
hexagonal lipid phase in the pure lipid. CLs consist of two
phosphatidylglycerol units connected via a glycerol backbone,
so as to form a dimeric structure (Figure 3). The polar “head”
carries two negative charges, whereas the hydrophobic “tails”
bear four acyl chains. The polar head has remained unmodiﬁed
during the course of evolution, but the fatty acid residues
have undergone modiﬁcations to both their chain length and
degree of unsaturation. The eukaryotic CLs have long acyl
chains and are polyunsaturated (18:2, 18:3, 22:6), whereas CLs
from prokaryotes have much shorter acyl chain lengths and are
fully saturated or mono-unsaturated. These diﬀerences reﬂect
an adaptation to the transition from anaerobic to aerobic
metabolism – the polyunsaturated fatty acid tails in eukaryotic
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FIGURE 3 | Biosynthesis and remodeling of cardiolipin. Putative pathways of CL biosynthesis, remodeling, and degradation in mammalian cells. Note that the
length of the acyl chains in the final phospholipids does not reflect their true length, which is typically 16C, 18C, or 22C, nor their degree of unsaturation.
Abbreviations: ALCAT 1, Acyl-CoA:lysocardiolipin acyltransferase 1; CDP-DAG, cytidine diphosphate-diacylglycerol; CDS, CDP-DAG synthase; CS, CL synthase;
CMP, cytidine monophosphate; CTP, cytidine triphosphate; DLCL, dilyso-CL; FFA, free fatty acid; G3P, glycerol-3-phosphate; LPC, lysophosphatidyl choline; LPE,
lysophosphatidylethanolamine; MLCL, monolyso-CL; MLCLAT 1, MLCL acyltransferase 1; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG,
phosphatidylglycerol; PG-P phosphatidylglycerol phosphate; PGPP, phosphatidylglycerol phosphate phosphatase; PGPS, phosphatidylglycerol phosphate synthase;
Pi, inorganic phosphate; PLA2, phospholipase A2; tafazzin, transacylase. [Reprinted, with permission of the authors and modified from (Chicco and Sparagna, 2007;
Mejia et al., 2014b; Ren et al., 2014) and with information from Claypool and Koehler (Claypool and Koehler, 2012), and also from the American Journal of Cell
Physiology, edited by the American Physiology Society, USA).
CLs can undergo oxidation and be used in signaling (Tyurina
et al., 2014a).
Most phospholipids are synthesized in the endoplasmic
reticulum (ER), and some are then imported into the
mitochondria [reviewed in (Hatch, 2004; Horvath and Daum,
2013)]. CL is unique because it is synthesized exclusively in the
mitochondria [reviews: (Chicco and Sparagna, 2007; Ji et al.,
2012; Kagan et al., 2014; Mejia et al., 2014b; Ren et al., 2014)]. In
CL synthesis (Figure 3), once phosphatidic acid (PA) reaches the
matrix side of the IMM, it is converted into cytidine diphosphate-
DAG (CDP-DAG) and pyrophosphate, through reaction with
cytidine triphosphate (CTP). This reaction is catalyzed by
CDP-DAG synthase (CDS), the importance of which has been
demonstrated in yeast ER and mitochondria (Kuchler et al.,
1986; Shen et al., 1996). The conserved IMM-resident Tam41p is
the mitochondrial CDP-DG synthase responsible for generating
the CDP-DAG for CL biosynthesis (Tamura et al., 2006, 2013;
Kutik et al., 2008; Tamura and Endo, 2013). CDS proteins in
the ER provide the CDP-DAG for phospholipid biosynthesis,
and TAMM41 supplies the CL pathway (Horvath and Daum,
2013). The downstream enzymes required for the biosynthesis
of PG and CL are also located on the matrix-facing leaﬂet of the
membrane. The commitment step in this pathway is catalyzed
by phosphatidylglycerol phosphate (PGP) synthase (PGS1),
which forms PGP from CDP-DAG and glycerol 3-phosphate
(Chang et al., 1998a). PGP is then rapidly dephosphorylated
to PG by PTPMT1 (Xiao et al., 2011; Zhang et al., 2011), an
enzyme from the protein tyrosine phosphatase family displaying
no primary sequence similarity to the yeast PGP phosphatase,
Gep4p (Osman et al., 2010). In the steady state, PG is present at
much lower levels (1–2%) than the other major mitochondrial
phospholipids (Daum, 1985), consistent with rapid consumption
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of the newly synthesized PG by downstream pathways. Finally,
cardiolipin synthase (CLS), an integral IMM protein with
its active site facing the matrix (Schlame and Haldar, 1993),
condenses PG with another molecule of CDP-DAG, to generate
nascent unremodeled CL (Chang et al., 1998b; Chen et al., 2006;
Lu et al., 2006). The defective acylation of CL with unsaturated
fatty acids and a decrease in total CL levels are important
biochemical signs of BTHS.
The functions of CLs initially identiﬁed were associated with
their structural roles in the organization of lipid bilayers and
deﬁnition of the curvature properties of membranes, together
with their ability to interact with components of the respiratory
complexes (Figure 4). CLs have recently been shown to associate
with and modify the functions of several proteins, inn particular,
a number of key IMM enzymes involved in the respiratory
chain (RC), including cytochrome c oxidase and ATP synthase,
carnitine palmitoyl-transferase, creatine phosphokinase, the
pyruvate translocator, mono-, di-, and tricarboxylate carriers,
glycerol-3-phosphate dehydrogenase, the phosphate transporter,
and ATP/ADP translocase (Ardail et al., 1990; Schlame et al.,
2000; Houtkooper and Vaz, 2008). A recent study used a
molecular dynamics simulation model of the cytochrome c
oxidase complex (complex IV) to show that there are precise CL
binding sites at the entrance to the proton channels on the matrix
side of the complex. Given the ability of CL to trap protons,
the authors suggested that CL might also play an active role in
transporting protons across complex IV to the intermembrane
space (Arnarez et al., 2013). CL may be considered to function as
a type of “glue”, holding the mitochondrial RC supercomplexes
together to ensure that electron ﬂow and proton transport
are as eﬃcient as possible (Zhang et al., 2002) (Figure 4).
CLs are absolutely required for the activity of some of these
respiratory enzymes, and their interactions with mitochondrial
proteins are speciﬁc. The activity of these enzymes is not fully
reconstituted if the CL is replaced with other phospholipids
(Schlame and Ren, 2009; Ren et al., 2014). As CL may regulate
ATP generation in cells, the maintenance of appropriate amounts
of CL in the mitochondria is essential for correct mammalian
cell function. This ﬁnding is consistent with the hypothesis that
CL is responsible for maintaining the structural integrity of the
FIGURE 4 | Cardiolipin as a “glue” optimizing electron transport within the electron transport chain supercomplex. (A) CL microlocalization on cristae
membranes, “gluing” the respiratory complexes (Zhang et al., 2002) together to form supercomplexes, thereby decreasing the distance between redox partners. In
addition to providing a platform for the aggregation of respiratory complexes, CL is also thought to serve as a proton trap (Haines and Dencher, 2002) on the outer
leaflet of the IMM, mediating the rapid lateral diffusion of protons to the ATP synthase with minimal changes in bulk phase-pH. ADP, adenosine diphosphate; ATP,
adenosine triphosphate; FADH2, reduced flavin adenine dinucleotide; FAD+, oxidized flavin adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide;
NAD+ oxidized nicotinamide adenine dinucleotide. (B) CL is a dimeric phospholipid with a small acidic head group and four acyl chains, resulting in a conical
structure and a large surface area. As a result of its conical shape, CL exerts lateral pressure on a membrane containing other phospholipids, such as
phosphatidylcholine (PC), resulting in curvature of the membrane and the proteins it contains.
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FIGURE 5 | Functions of cardiolipins, modifiers of Barth syndrome. CL
is involved in a plethora of cellular events and signaling pathways. The tafazzin
mutations affect the CL acyl chain length and its degree of saturation and the
synthesized CLs stay saturated instead of being converted into mature CL
with unsaturated acyl chains. This impacts all CL-related functions that are
listed in the Figure. IRGM; Immunity-related GTPase family, M [(human)],
OPA1; Dynamin-like 120 kDa protein, mitochondrial encoded by the gene
OPA1.
proton-conducting protein environment and directly involved
in proton uptake. The maintenance of appropriate levels of CL
in mitochondria is therefore essential for correct cell function
(Figure 5).
The key contribution of mitochondria to metabolic pathways
and cell death or autophagic mechanisms requires sophisticated
signaling systems (Li et al., 2015), where various lipid mediators,
derived from polyunsaturated fatty acids, are essential. A range
of diversiﬁed polyunsaturated molecular oxidation products is
produced from CL by interaction with the intermembrane
space hemoprotein, cytochrome c. Various oxygenated CL
species undergo phospholipase A2-catalyzed hydrolysis to
generate oxygenated fatty acids, including well known lipid
mediators, such as oxygenated linoleic and arachidonic acids and
monolysocardiolipins (MLCLs). These reactions constitute a new
biosynthetic pathway for the production of lipid mediators and
this pathway is activated in vivo after acute tissue injury (Tyurina
et al., 2014a,b).
However, CLs also play a key role in many other cellular
processes (Figure 4), including apoptosis (Choi et al., 2007;
Gonzalvez et al., 2008), autophagy (Chu et al., 2013, 2014),
cell cycle regulation (He et al., 2013; Chao et al., 2014) and
iron homeostasis (Patil et al., 2013). There are currently several
lines of evidence to support the notion that mitochondria (with
deleterious ROS production) are autophagic substrates capable of
shaping autophagic responses in diverse ways (Figure 6) (DeVay
et al., 2009; Ban et al., 2010; Rambold and Lippincott-Schwartz,
2011; Chu et al., 2013, 2014).
TAFAZZIN FUNCTION
As already mentioned, tafazzin is a ubiquitous mitochondrial
enzyme that catalyzes acyl transfer from a phospholipid to
a lysophospholipid (Figure 3). The TAZ gene encodes for a
protein or proteins responsible for speciﬁc remodeling of the
CL to generate tetralinoleoyl cardiolipin (L4-CL), the principal
constituent of CL in the heart.
Mammals have at least three enzymes capable of re-
acylating MLCL: tafazzin [also cited by Xu et al. (2006)
to be a “phospholipid-lysophospholipid transacylase”], MLCL
acyltransferase 1 (MLCLAT1), and acyl-CoA:lysocardiolipin
acyltransferase-1 (ALCAT1). Tafazzin is the only one of these
three enzymes to have been conserved during evolution, from
yeast to higher eukaryotes (Taylor andHatch, 2003; Lu et al., 2006;
Saini-Chohan et al., 2009; Claypool and Koehler, 2012). All the
evidence obtained to date indicates that tafazzin is responsible
for most of the CL remodeling occurring under physiological
conditions. Tafazzin deﬁciency is characterized biochemically by
an increase in MLCL (remodeling intermediate) levels, a decrease
in CL (both the substrate and product) levels and an abnormal
acyl chain proﬁle in the remaining CL (Valianpour et al., 2005;
Claypool et al., 2006, 2011; Houtkooper et al., 2009). However,
the mechanism by which tafazzin establishes the steady-state
acyl chain composition of CL remains unclear. tafazzin catalyzes
a reversible transacylation reaction that displays no intrinsic
acyl chain speciﬁcity, acts on acyl chains at both the sn-1 and
sn-2 positions, and can use virtually any phospholipid and its
lyso-derivatives as fatty acyl donor and acceptor, respectively (Lu
et al., 2006; Malhotra et al., 2009).
Over 100 diﬀerent pathogenic mutations have been identiﬁed
throughout the gene giving rise to clinical signs. A list of
known genetic variants is maintained by the Barth Syndrome
Foundation https://www.barthsyndrome.org/science (Clarke
et al., 2013). These mutations include missense and non-sense
changes (Johnston et al., 1997), splicing defects, full or partial
deletions and frame shifts. One of the main problems in studies
of tafazzin is the alternative splicing of the primary transcript,
resulting in diﬀerent mRNAs and, potentially, diﬀerent proteins
(Bione et al., 1996). The tafazzin gene produces four main
alternatively spliced mRNAs including full length (FL), exon
5 skipped (delta5, 5), exon 7 skipped (delta7,7), and both
exons 5 and 7 skipped (delta5/7, 57) (Kirwin et al., 2014).
Kirwin et al. (2014). observed that a fraction of the minor splice
variants can be predicted to be non-productive. Ronvelia et al.
(2012) provided clear evidence that a single mutation can give
rise to diﬀerent clinical signs (phenotypes). Thus, although two
patients had the same mutation, the infant displayed severe,
characteristic features of BTHS (with congestive heart failure
requiring heart transplantation at 11 months of age), whereas the
great uncle presented only myopathy, not diagnosed until he was
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FIGURE 6 | Mitochondrial dysfunctions due to tafazzin mutations lead to ROS production, CL translocation and dysregulation of autophagic
signaling. CL is synthesized in the inner leaflet of the IMM by cardiolipin synthase (CLS). This is also the localization where it can be remodeled by tafazzin and
monolysocardiolipin acyltransferase (MLCLAT), in a balanced system with PLA2. During processing or following stress signaling, CLs may also be translocated to the
OMM and ER for remodeling, whereas in healthy mitochondria most of the CL remains at its site of synthesis in the IMM. The externalization of mature CL to the
mitochondrial surface, through a mechanism involving phospholipid scramblase-3 (PLSR3), is a prerequisite for its recognition by light chain 3 protein (LC3) as a
mitophagic “eat-me signal” targeting dysfunctional mitochondria to the autophagosomal machinery. The precise mechanism of scramblase regulation remains
unclear, but its action may be physically facilitated by the proximity of nucleoside diphosphate kinase (NDPK-D). NDPK-D regulates the balance between di- and
tri-phosphonucleotides, which provide GTP for the GTPase activity of a dynamin-like protein encoded by the gene OPA1 (for optic atrophy gene 1). By forming a
hexamer in the intermembrane space, NDPK-D forms a physical bridge between the IMM and OMM. The switch from the phosphotransfer mode to a
CL-translocating mode would thus facilitate the redistribution of CLs between the IMM and OMM. Note that immature CLs containing saturated acyl chains are gray
while mature CLs with unsaturated acyl chains are blue. [Figure reproduced with modifications from Kagan et al. (2014), with the permission of the authors and of
Elsevier Press].
43 years-old. This suggests that there are modifying factors that
act as key determinants of the clinical progression of BTHS.
Expression studies with the tafazzin splice variants in tafazzin-
deﬁcient yeast (taz) showed that only the human tafazzin
variant lacking exon 5 could fully restore the aberrant CL
proﬁle of the taz mutant. The full-length tafazzin variant only
partially restored the CL proﬁle. Protein sequence alignment
suggested that exon 5 in the human tafazzin gene was introduced
later in evolution, because it is absent from the corresponding
genes of lower organisms (Vaz et al., 2003; Gonzalez, 2005).
This hypothesis was conﬁrmed by tafazzin gene analysis, which
showed that the exon 5 sequence was present in all mammalian
species tested, whereas the splice recognition site required for
the incorporation of exon 5 into the mRNA was present only
in primates. As CL composition is identical in primates (i.e.,
with mRNA transcripts containing exon 5) and other mammals
(i.e., lacking exon 5), and the full-length human tafazzin was
unable to restore the CL proﬁle of taz yeast fully, it is important
to determine the function of this full-length variant in CL
metabolism. BTHS patients with a mutation in exon 5 [“Human
Tafazzin (TAZ) Gene Mutation and Variation Database”; www.
barthsyndrome.org] have recently been identiﬁed. Theoretically,
these patients should have normal levels of the tafazzin variant
lacking exon 5 if the mutation does not render the initial
transcript unstable or triggers its degradation. It would be very
interesting to investigate the expression of the diﬀerent tafazzin
mRNA variants andmore importantly the levels of CL andMLCL
in these patients.
The presence of the various splicing variants and the apparent
lack of correlation between the genotype and clinical phenotype
of BTHS patients greatly complicate the task of designing
experiments to understand BTHS pathogenesis (Johnston et al.,
1997). Information about tafazzin mRNA levels, protein levels,
and enzymatic activities, required for comparisons of genotype
and phenotype, is missing. New ﬁndings are gradually emerging,
but both quantitative protein analyses by immunoblotting and
enzymatic activity measurements are still hampered by the
experimental diﬃculties. A quantitative mRNA analysis has
been developed for the diﬀerent tafazzin splice variants, and
this should make it possible to compare mRNA levels in the
cells and/or tissues of control subjects and BTHS patients, and,
therefore, determine whether there is at least a correlation
betweenmRNA levels and genotype, if known. For instance, some
tafazzin mutations may lead to an increase in transcription or the
selective degradation of mRNAs.
TAFAZZIN LOCALIZATION AND
ORGANIZATION
The localization of lipid biogenesis proteins within the
mitochondrial membranes is not straightforward. CLS (Crd1p)
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was no exception, but was eventually localized to the matrix-
facing leaﬂets of the inner membrane, where it catalyzes the
synthesis of CL (Schlame and Haldar, 1993). We still know little
about the submitochondrial location of endogenous mammalian
tafazzin. Until very recently, the import into mitochondria and
the assembly of tafazzin have only been studied in yeast. The
yeast transacylase Taz1p was localized to the IMM and OMM
facing the intermembrane space (Brandner et al., 2005; Claypool
et al., 2006; Gebert et al., 2009; Xu et al., 2015). The Taz1p
transacylase is imported into mitochondria and sorted to the
OMM by a non-canonical targeting sequence, as it contains no
typical N-terminal mitochondrial targeting sequence (Claypool
et al., 2006). As mitochondrial targeting is undoubtedly driven by
an internal targeting sequence, Taz1p probably inserts into a loop
of the TOM complex facing the intermembrane space (Herndon
et al., 2013). This situation appears to be radically diﬀerent from
that for the deacylase (Cld1p) reinitiating CL remodeling, which
is located in the matrix leaﬂet of the IMM (Baile et al., 2013). This
implies a more complex mechanism for the MLCL produced on
the matrix side of the IMM in yeast. Due to its primary location,
MLCL must either ﬂip across the membrane or be transported
to the OMM to gain access to tafazzin for remodeling (Baile
et al., 2014). Tafazzin has been conserved as a CL remodeling
enzyme in eukaryotes, suggesting that the mammalian tafazzin
is likely to be located at a similar position within mitochondria.
The localization of tafazzin might provide information about the
complex mechanisms of CL and MLCL traﬃcking required to
provide these molecules with access to tafazzin for remodeling
(Baile et al., 2014). Tafazzin reacts indiscriminately with all
phospholipid and lysophospholipid species, but it requires its
substrates to be presented in a non-bilayer state (Schlame, 2013).
This suggests that the propensity of CL to form non-bilayer
structures is one of the key features underlying its suitability
as the primary substrate of tafazzin. Tafazzin is anchored to
the membrane by an internal peptide segment, which does not
cross the membrane but protrudes into its hydrophobic interior
(Claypool et al., 2006). Tafazzin appears to interact with protein
complexes of various sizes (Claypool et al., 2006, 2008; Xu et al.,
2015). Most of these complexes have an apparent mass of 400 kDa
or less, but some tafazzin seems to be associated with larger
supercomplexes that also contain the ADP-ATP-carrier and the
ATP synthase (Claypool et al., 2008). Such supercomplexes form
only if CL is present in the membrane. One recent study focused
on tafazzin complexes extracted from isolated mitochondria
from Drosophila and mammalian cell cultures (Xu et al., 2015).
Tafazzin is thought to bind to multiple protein complexes in
these organisms, in interactions that lack speciﬁcity. Very large
tafazzin complexes were detected only in the presence of CL,
whereas smaller complexes remained intact even after treatment
with phospholipase A2. In mammalian cells, tafazzin has a half-
life of only 3–6 h, much shorter than that of other mitochondrial
proteins. This suggest that tafazzin is a transient resident of
multiple protein complexes (Xu et al., 2015). Linked to that, it
appears that during its short lifetime, tafazzin exchanges acyl
groups between diverse membrane phospholipids, a reaction
that is thought to support ﬂuctuating membrane dynamics or
cristae membrane assembly by lowering the energy of curvature
formation (Schlame et al., 2012a). Eﬀectively, tafazzin catalyzes
an unusual type of reaction in terms of classical enzymology,
as the signal transduction network is usually dominated by
highly speciﬁc chemical reaction linked to and driven by a
decrease in free energy. The enzymatic reaction driven by
tafazzin is both non-speciﬁc and reversible. The main function
of tafazzin appears to be conferring considerable “composition
ﬂexibility” on mixtures of lipids, through transacylation to
generate molecules with the characteristics described above.
The transacylation events minimize the energy of the lipid
population more eﬀectively than that of a particular species still
in the lipid phase state. Indeed, tafazzin senses the conformation
of the membrane through its curvature (controlled principally
by CL insertion), selecting curvature-prone molecular species
of CL (Gawrisch, 2012; Schlame et al., 2012a). Tafazzin may
also interact with a protein complex formed by prohibitins and
DNAJC19 for CL remodeling (Richter-Dennerlein et al., 2014).
A recent three-dimensional (3D) homology modeling of
tafazzin allows the identiﬁcation of amino acid residues
correlated to CL binding and to mitochondrial membrane
linkages that facilitate the acyl-transfer reactions (Hijikata et al.,
2015). Exon 5 of the protein is predicted to be an intrinsically
unstructured domain that may change the substrate aﬃnity
and/or determine the primate-speciﬁc molecular interactions. In
contrast, exon 7 certainly encodes part of the “putative” substrate
binding cleft because gene products lacking exon 7 lose the
substrate binding capacity (Hijikata et al., 2015). It was also
recently reported that tafazzin functional activity is required to
provide mature CL that is selectively involved in the execution
of mitophagic processes. Indeed, tafazzin deﬁciency caused
defective mito-phagosome biogenesis, but did not aﬀect other
autophagic processes (Hsu et al., 2015). This is an important point
that links straightforward tafazzin deﬁciency and CL alterations
to impaired oxidative phosphorylation, ROS production and
execution of speciﬁc autophagic events or, more speciﬁcally,
mitophagic processes.
There is a major need for biochemical investigations to
determine the submitochondrial localization of tafazzin at higher
resolution and to answer key questions. For example, the precise
site and context of CL remodeling remain to be determined. It
remains unclear whether this process occurs at contact sites, at
junctions between cristae, at the tips of cristae, or whether it
is conﬁned to hemifusion membrane zones. It would also be of
interest to deﬁne the composition of the protein complexes with
which tafazzin associates. Which proteins interact with tafazzin
and what are their functions? CL remodeling must be considered
in the context of CL ﬂexibility and metabolism, and questions
about the relationship between the sites of CL biosynthesis and
remodeling remain to be answered. The timing of CL remodeling
in terms of the life span of CL species may also be important.
A role for biosynthetic enzymes other than tafazzin in remodeling
cannot be ruled out. The lack of involvement of a phospholipase
in CL remodeling (as tafazzin regenerates lysophospholipids,
and monolysocardiolipin in particular) does not rule out the
possible involvement of other enzymes, such as lipases and acyl
transferases. Overall, the biological characteristics of tafazzin
required for its function in CL remodeling remain unclear.
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CL REMODELING
As mentioned earlier, CL synthesis (Figure 3) in mammals
occurs only in mitochondrial membranes and is evolutionarily
conserved in Eukaryotes (Schlame and Haldar, 1993). Newly
synthetized CL is produced in the inner leaﬂet of the IMM
(Figure 6) (Schlame and Haldar, 1993; Dzugasová et al., 1998;
Osman et al., 2010). The presence of CL in both leaﬂets of the
IMM as well as in the OMM is now widely accepted and this
ﬁnal distribution of CL must involve traﬃcking steps even if
the mechanisms and the players responsible for such processes
are still poorly understood. Newly synthesized CL is immature,
characterized by saturated acyl chains of variable length and
asymmetry around the central carbon of the bridging glycerol
(Schlame et al., 2005; Schlame and Ren, 2006). CL maturation
therefore necessitates acyl chain remodeling. CL remodeling
starts by the action of a phospholipase that removes an acyl
chain forming MLCL, then reacylated by an acyl transferase or
a transacylase to form mature CL (Figure 3). The mature Cl
are characterized by their unsaturated acyl chains and a high
degree of symmetry (Schlame et al., 2005; Claypool and Koehler,
2012).
Within the three distinct CL remodeling pathways described
in mammals, tafazzin (Taz1p in yeast, the only remodeling
enzyme identiﬁed there), is a MLCL transacylase which removes
an acyl chain from another phospholipid (with a preference
for PC or PE) and transfer it to MLCL, thus regenerating
CL, but in a fully mature form (Xu et al., 2003, 2006). Two
other enzymes are involved in mammalian CL remodeling. The
MLCL acyltransferase 1 (MLCLAT1) in pig liver mitochondria
exhibits a speciﬁcity for linoleate and resides on the inner
leaﬂet of the IMM (Figure 6) (Taylor et al., 2012). Interestingly,
the overexpression of MLCLAT1 in lymphoblasts derived from
BTHS patients led to an increased incorporation of linoleic
acid into CL. Conversely, RNAi knockdown of MLCLAT1
in Hela cells led to a lower incorporation of linoleic acid
into CL (Taylor et al., 2012). However, a third enzyme, acyl-
CoA:lysocardiolipin acyltransferase 1 (ALCAT1), is located in
the Mitochondrial Associated Membrane of the ER (MAM)
where phospholipid traﬃcking between the ER and the
mitochondria takes place. ALCAT1 shows no speciﬁcity for
linoleic acid and catalyzes the CL remodeling by incorporating
long-chain polyunsaturated fatty acid chains into CL. The
resulting CLs, more susceptible to oxidative damage, are
associated with early CL peroxidation (Ng et al., 2005). Recently,
ALCAT1 has been implicated in mitochondrial biogenesis (Li
et al., 2012). Curiously, but not surprisingly considering its
localization at the MAM complexes (OMM), overexpression of
ALCAT1 causes oxidative stress, which leads to mitochondrial
fragmentation andMitofusin 2 depletion. Furthermore, ALCAT1
overexpression leads to mtDNA instability and depletion that are
reminiscent of Mfn2 deﬁciency. Accordingly, the expression of
Mfn2 rescues mitochondrial fusion and respiratory dysfunction
(Li et al., 2012). ALCAT1 removal prevents mitochondrial
fragmentation from oxidative stress by up-regulating Mfn2
expression, mtDNA copy number, and ﬁdelity of mtDNA
transcription (Liu et al., 2012). So, ALCAT1, which diﬀers
in localization from the two other CL remodeling enzymes,
tafazzin and MLCLAT1, reveals an unexpected role of CL
remodeling, linking oxidative stress to mitochondrial fusion
defects.
BARTH SYNDROME MODELS BRIDGING
THE GAP BETWEEN TAZ MUTATIONS
AND THE PHYSIOPATHOLOGICAL
FEATURES OF THE DISEASE
Several BTHS models are available, and they all display the
characteristic biochemical defects underlying BTHS: high levels
of MLCL, low levels of CL, and an abnormal acyl chain
composition of the remaining CL, resulting in bioenergetic
destabilization of the mitochondria.
Pioneering Studies Using Yeast as a
Model System
Genetic approaches to the investigation of BTHS mutations have
greatly beneﬁted from the yeast model (Joshi et al., 2009; Ye et al.,
2014). Indeed, all the known missense mutations of the tafazzin
gene were reconstituted in two sets of experiments. Claypool et al.
(2011) established 21 diﬀerent pathogenic missense mutations of
TAZ in yeast Taz1p (Saccharomyces cerevisiae) (Claypool et al.,
2011) out of which 18 could not replace functional endogenous
tafazzin. Biochemical and cell characterization was subsequently
carried out for the last three of the 21 yeast BTHS mutants,
resulting in the establishment of three additional modes of
tafazzin dysfunction (Whited et al., 2013) and the elucidation
of their loss-of-function mechanisms. In summary, in-depth
characterization of the yeast BTHS-mutant panel has identiﬁed
seven functional classes of mutations found in BTHS, deﬁned on
the basis of their loss-of-function mechanisms (Claypool et al.,
2006, 2011; Whited et al., 2013).
The seven classes of variants are: (1) non-functional truncated
products resulting from frame shifts or aberrant splicing, (2)
products that are mislocalized within mitochondria and prone to
aggregation, (3) aberrantly assembled products, (4) catalytically
dead products, (5) hypomorphic alleles encoding products with
residual transacylase activity, (6) products unable to engage
in stable productive assemblies, and (7) temperature-sensitive
products.
The systematic screening of pathogenic variants has provided
important mechanistic insights into the origin of the clinical
heterogeneity of BTHS. It might be possible to translate the
biochemical characteristics observed in yeast model systems into
useful clinical applications for disease treatment if the deﬁned
loss-of-function mechanisms are conserved in an appropriate
mammalian model.
Pioneering studies on yeast carried out in Greenberg’s
laboratory and others (Chen et al., 2008) have suggested that
there is a relationship between TAZ gene deletion, mitochondrial
malfunction and ROS production, as indicated by the following
evidence (Table 2):
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TABLE 2 | Consequences of TAZ mutations and subsequent tafazzin deficiency in multiple BTHS models.
Model organism General phenotype Mitochondrial events
Yeast
Saccharomyces cerevisiae
• Temperature-sensitive growth on a non-fermentable
carbon source
• Abnormal morphology
• Partial uncoupling
• Reduced osmotic stability
• Increased oxidative stress ∗
• Reduced stability of respiratory supercomplexes
• Disruption of iron homeostasis
Fly Drosophila
melanogaster
• Flight muscle weakness
• Defective spermatogenesis
• Abnormal morphology of the flight muscle
• Inner membrane aggregation
• Reduced state-3 respiration
• Reduced dimerization and dimer row formation by ATP synthase
Zebrafish
Danio rerio
• Early lethality
• Abnormal embryogenesis and cardiac development
Mouse
Mus musculus
• Prenatal and perinatal mortality
• Low body weight
• Developmental cardiomyopathy
• Adult cardiomyopathy (dilated type)
• Skeletal muscle weakness
• Hyperproliferation of cardiac mitochondria
• Abnormal morphology
• Reduced crista density
• Disrupted alignment between mitochondria and myofibrils
Human
Homo sapiens
• Fetal loss and stillbirth
• Abnormal growth
• Chronic fatigue
• Cardiomyopathy
• Skeletal muscle weakness
• Neutropenia
• Abnormal morphology
• Inner membrane aggregation
• Smaller membrane potential (Ψm)
• Reduced state-3 respiration
• Reduced stability of the respiratory RCs
• Slight increase in ROS production
• Release of cytochrome c and stimulation of apoptosis in progenitor cells
• Resistance to Fas and TNFα-induced apoptosis
• Disrupted alignment between mitochondria and myofibrils
Very important clues from the yeast cell model are shown in red, whereas shared characteristics are shown in blue. ∗ Indicates essential discoveries taken into account in
the recent work on human induced pluripotent stem cells (hiPSC).
- Subcellular fractionation showed that the taz1 protein was
located exclusively in mitochondria in yeast (Ma et al., 2004).
- The yeast tafazzin protein displays a mitochondrial acyl-CoA
dependent lysophosphatidylcholine (lyso-PC) acyltransferase
activity related to triacylglycerol and mitochondrial lipid
synthesis (Testet et al., 2005).
- Energy coupling in taz1 mitochondria is dependent on the
rate of oxidative phosphorylation.
- Membrane stability is compromised in taz1 mitochondria
exposed to high temperature and hypotonic conditions. This is
also the case for the yeast CLS mutant, CRD1 (Zhong et al.,
2004; Zhang et al., 2005). Coupling was measured in taz1
mutant cells containing diﬀerent splice variants of the human
TAZ gene. Only the variant that restores wild-type CL synthesis
(lacking exon 5) restored coupling under hypotonic conditions
and at high temperature (Ma et al., 2004).
- In response to ethanol, taz1 and crd1 mutants (Koshkin
and Greenberg, 2000), which cannot synthesize CL, display
high levels of protein carbonylation, an indicator of ROS
production (Chen et al., 2008). The increase in ROS
production was probably not due to defects in the defense
systems protecting against oxidative stress, because the
CL mutants were not sensitive to paraquat, menadione,
or hydrogen peroxide (H2O2) (Chen et al., 2008). High
levels of protein carbonylation can be rescued by oleic
acid supplementation in the taz1 mutant, but not in
the crd1 mutant. This suggests that oleoyl-CL and/or
oleoyl-monolyso-CL allow the taz1  mutant to grow in
ethanol by decreasing oxidative stress. However, although
RC dysfunction is usually considered to be a reason for
searching for superoxide anions (Brand, 2010)and hydrogen
peroxide production, interest in the correlation between
tafazzin depletion and deleterious ROS production in BTHS
is very recent (Gonzalvez et al., 2013).
Mitochondria are the site of iron-sulfur cluster biosynthesis,
and the iron-sulfur clusters are exported to the rest of
the cell to be used by a range of enzymes (Lill, 2009).
Patil et al. (2013) showed that the loss of CL in the
crd1 mutant led to an increase in the expression of iron
uptake genes, associated with high levels of mitochondrial
iron and high sensitivity to iron and hydrogen peroxide
most likely due to the Fenton reaction producing the very
reactive hydroxyl radical (Moller et al., 2011). Indeed, high
mitochondrial iron levels result from the disruption of iron-
sulfur (Fe-S) cluster biogenesis. Furthermore, crd1 cells
have low levels of activity for mitochondrial Fe-S enzymes
(aconitase, succinate dehydrogenase, and ubiquinol-cytochrome
c oxidoreductase) and cytosolic Fe-S enzymes (sulﬁte reductase
and isopropylmalate isomerase), demonstrating that the loss of
CL aﬀects mitochondrial Fe-S biogenesis. Although not entirely
related, we can speculate that mitochondrial Fe-S biogenesis is
disturbed in the taz1 mutant as well as in cells derived from
human patients’ tissues.
In conclusion, research using the yeast cell model has provided
a large body of results and hypotheses useful for future studies of
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BTHS, and greater use could be made of this system to investigate
the pathogenesis of this rare disease.
Barth Syndrome Models
Other whole-organism models including taz-depleted zebraﬁsh
(Khuchua et al., 2006), taz−/−fruit ﬂies (Xu et al., 2006, 2009;
Schlame et al., 2012b) and a mouse model of the BTHS are
now available (Acehan et al., 2011; Soustek et al., 2011; Phoon
et al., 2012). Many cellular models are available with patient-
derived ﬁbroblasts (Barth et al., 1996), lymphoblasts (Xu et al.,
2005; Gonzalvez et al., 2008, 2013), neutrophils (Kuijpers et al.,
2004; van Raam and Kuijpers, 2009), iPSCs (Dudek et al., 2013;
Wang et al., 2014a) and taz-depleted rodents (Acehan et al., 2009;
He, 2010; He et al., 2014). In both zebraﬁsh (Khuchua et al.,
2006) and taz-depleted mice (Acehan et al., 2011; Soustek et al.,
2011; Phoon et al., 2012), the cardiac defects observed reproduce
many of the relevant cardiac parameters noted in BTHS patients.
In zebraﬁsh, TAZ knockdown severely impairs development,
and the degree of cardiac dysmorphology is proportional to the
dose of morpholino administered (Khuchua et al., 2006). In
addition to impaired cardiac function, TAZ knockdown mice
have an abnormal skeletal muscle ultrastructure, with a disrupted
sarcomeric spatial organization (Acehan et al., 2011). These
muscle abnormalities are consistent with the data obtained for
taz−/−fruit ﬂies, which also have impaired muscle functions (Xu
et al., 2006).
Many cellular models of BTHS display dysmorphic changes in
mitochondrial morphology and energetic defects (Acehan et al.,
2007, 2009; Gonzalvez et al., 2008, 2013), in patient-derived
lymphoblasts (Xu et al., 2005; Gonzalvez et al., 2008, 2013),
iPSCs (Dudek et al., 2013) and ﬁbroblasts (Barth et al., 1996).
These cell types also display low basal respiration levels, a low
membrane potential, and compromised coupling of oxidative
phosphorylation (OXPHOS). Respiratory supercomplexes (SCs)
have abnormally low levels of enzymatic activity, and there is
a shift in supercomplex assembly from large “respirasomes” to
smaller, and presumably less eﬃcient, SCs (McKenzie et al., 2006;
Dudek et al., 2013; Gonzalvez et al., 2013). These alterations to
RC assembly also increase ROS production.
However, each model has its own characteristics (Table 2). For
example, the shRNA-inducible TAZ knockdown mouse displays
a basal respiration that is lower than normal levels of maximal
uncoupled respiration. Tafazzin knockdown mice display a
marked impairment of oxygen consumption during exercise,
with no signiﬁcant eﬀect on resting metabolic rates. CL deﬁciency
results in a signiﬁcantly lower than normal mitochondrial
respiratory reserve capacity in neonatal cardiomyocytes. This
decrease probably reﬂects the low level of activity of complex
III, which requires CL for its assembly and optimal activity.
These ﬁndings suggest a bioenergetic dysfunction similar to that
observed in cell culture-based models. Changes in respiratory SC
stability are suspected, but have yet to be demonstrated (Bowron
et al., 2013).
The results from the various BTHS models indicate that the
cardiolipin abnormalities that occur in the absence of tafazzin
result in an OXPHOS dysfunction involving respiratory super-
complex destabilization. These RC dysfunctions are associated
with the production of ROS (mostly superoxide anions with local
toxicity and, subsequently, hydroperoxides, which participate in
deleterious signal transduction) (Gonzalvez et al., 2013). The
“long-term” consequences of these eﬀects may compromise heart
development and function.
Two key studies relied on neonatal cardiac ﬁbroblasts and
cardiac myocytes (He, 2010; He et al., 2013). The authors found
that TAZ knockdown resulted in the hypertrophy of neonatal
cardiac myocytes (He, 2010). In this case, the authors used an
adenovirus as the vector for transferring a tafazzin small hairpin
RNA (shRNA) into neonatal ventricular myocytes (NVMs) for
investigation of the eﬀects of tafazzin knockdown. The tafazzin
shRNA adenovirus consistently knocked down tafazzin mRNA
and CL levels, and signiﬁcantly decreased mitochondrial ATP
production. The phosphorylation of AMP-activated protein
kinase (AMPK) and the density of mitochondria were both
higher in tafazzin-knockdown NVMs than in control cells into
which a scrambled shRNA had been introduced. In assessments
of hypertrophy (in vitro tafazzin knockdown), overall surface
area, protein synthesis, and expression of the hypertrophic
marker gene encoding brain natriuretic peptide were all higher
in NVMs infected with the tafazzin shRNA adenovirus (He,
2010). According to Richter and Ruderman (2009) ATP depletion
in cardiac myocytes has several detrimental eﬀects, including
contractile dysfunction, hypertrophy, and production of ROS
potentially responsible for autophagy dysregulation and cell
death. ATP depletion switches on ATP-producing catabolic
pathways, such as fatty acid oxidation and glycolysis, and switches
oﬀ ATP-consuming anabolic pathways, such as lipogenesis and
glyconeogenesis. In the long term, mitochondrial ATP depletion
may be compensated by an increase in mitochondrial “mass” due
to enhanced mitochondrial biogenesis, mediated by activation
of the “fuel gage” AMPK (Figure 7) (Hardie, 2008). Jager
et al. (2007) reported that AMPK directly phosphorylated and
activated PGC-1, the key regulator of mitochondrial biogenesis.
Strength and endurance training leads to the consumption
of larger amounts of ATP, associated with an increase in
mitochondrial volume in the muscle (Reznick and Shulman,
2006). Tafazzin knockdown increases mitochondrial density in
NVMs, consistent with the notion that ATP depletion enhances
mitochondrial biogenesis (Figure 2).
This is also consistent with the large number of mitochondria
found in the lymphocytes of patients with BTHS (Xu et al., 2005;
Gonzalvez et al., 2013) (Figure 2). This greater mitochondrial
density contributes to an increase in the volume of NVMs
(cardiac myocytes have a very high mitochondrial density, likely
to inﬂuence cell shape) (Goﬀart et al., 2004) as observed in TAZ-
knockdown NVMs (thus, TAZ knockdown induced hypertrophy
in cardiomyoctes).
In primary cultures of neonatal ventricular ﬁbroblasts
(NVFs) infected with a tafazzin short hairpin RNA adenovirus,
tafazzin knockdown increased ROS production (He et al.,
2013) and induced mitogen-activated protein kinases and
protein and DNA synthesis via cell cycle regulators. It also
reduced intracellular ATP levels, activated AMPK, and caused
multinucleation, hypertrophy, and enhanced collagen secretion.
Tafazzin knockdown interrupts the NVF cell cycle, potentially
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FIGURE 7 | Tafazzin knockdown in neonatal cardiac fibroblasts.
Tafazzin gene knockdown results in mitochondrial dysfunction, with the
production of lower levels of ATP and higher levels of superoxide anions and
associated ROS. ROS activate MAPKs, induce gene expression factors and
cell cycle regulators and lead to cell cycle progression. Alternatively, ATP
deficiency may activate AMPK, leading to mitochondrial biogenesis and the
cessation of cell proliferation. Tafazzin knockdown ultimately results in
multinucleation, hypertrophy and enhanced collagen secretion [this scheme
is derived from the work of He and collaborators (He et al., 2013) and has
been freely interpreted with permission of the American Journal of
Physiology: Heart and Circulatory Physiology from the American Physiology
Society, USA].
contributing to the ﬁbrosis and dilated CM observed in BTHS.
It is possible that knocking down tafazzin in diﬀerent model
systems would result in a diﬀerent phenotype, because there
appears to be no correlation between genotype and phenotype
in BTHS. For instance, Tafazzin knockdown may have diﬀerent
eﬀects at diﬀerent stages of embryonic development.
USE OF HUMAN INDUCED
PLURIPOTENT STEM CELLS (HIPSC)
FOR THE MODELING OF
CARDIOMYOPATHIES
Advances in the understanding and treatment of cardiac
disorders have been thwarted by the inability to study beating
human cardiac cells in vitro, making it necessary to use other
models, such as yeast, Drosophila, zebraﬁsh, and animal or
transfected cells (as described above). Furthermore, the invasive
nature of the methods used to obtain human cardiac tissues has
hindered research in this area, which has progressed much more
slowly than hematological research, for example.
The recent development of iPSCs has now emerged as a
reliable method for producing patient-speciﬁc somatic tissue cell
lines via directed diﬀerentiation. iPSC-derived cardiomyocytes
(iPSC-CMs) provide a robust platform for studying genetic
cardiac disorders, because this approach makes it possible
to analyze and manipulate human cardiac cells in culture
(Figure 8). This model has already been shown to be
complementary or superior to transfected cell or animal
models of cardiac genetic disorders (Figure 9). iPSCs are
produced by reprogramming somatic cells to yield a more
pluripotent phenotype, with the capacity for self-renewal
and diﬀerentiation into derivatives of all three germ layers:
endoderm, mesoderm and epiderm [for reviews see (Matsa
et al., 2014; Sallam et al., 2014)]. This behavior was ﬁrst
described by Takahashi and Yamanaka (2006) and then by
Yu et al. (2007). Several groups subsequently showed that the
directed diﬀerentiation of these cells could produce somatic
cell derivatives, such as neurons, hematopoietic cells and
cardiomyocytes (Dimos et al., 2008; Kambal et al., 2011;
Mordwinkin et al., 2013).
Dey et al. (2009) and Slomka et al. (2012) recently performed
a detailed characterization of multiple stem cells and showed
that the diﬀerentiation of iPSCs led to a loss of immunogenicity,
resulting in tolerance induction, despite diﬀerences in antigen
expression between iPSC-derived cells and the original somatic
cells (de Almeida et al., 2014). Human induced pluripotent stem
cells (hiPSC) have been used to study the molecular mechanisms
of long-Q-Tc syndrome (Moretti et al., 2010; Matsa et al.,
2014), catecholaminergic polymorphic ventricular tachycardia
(Itzhaki et al., 2012; Jung et al., 2012), dilated CM [for review;
(Selem et al., 2013)], hypertrophic CM (Lan et al., 2013),
LEOPARD syndrome (Lan et al., 2013), arrhythmogenic CM
(Lombardi and Marian, 2010), Friedreich ataxia (Hick et al.,
2013), hypoplastic left heart syndrome (Gaber et al., 2013;
Kobayashi et al., 2014), Marfan syndrome (Quarto et al., 2012),
other congenital heart diseases and, more recently, BTHS (Wang
et al., 2014a).
Cardiovascular cells derived from patient-speciﬁc iPSCs
harbor gene mutations associated with the pathogenesis of
inherited cardiac diseases and congenital heart diseases. The
diﬀerentiation of disease-relevant and patient-speciﬁc iPSCs into
relevant cell types can relieve major limiting steps in disease
modeling and investigation. This approach makes it possible to
generate large amounts of appropriate cellular material for use
in mechanistic studies. It is now possible to develop appropriate
cell-based assays for assessing relevant aspects of the disease
studied (Figure 8):
A recent publication combined analysis of human iPSCs cells
together with genome editing, cell biology (including biochemical
aspects and bioenergetic) and physiological approach to highlight
new insights into BTHS-associated CM (Wang et al., 2014a).
Wang et al. (2014a) established patient-speciﬁc BTHS-iPSCs
lines containing frameshift or missense mutations of the TAZ
gene and used them to study BTHS. The authors used well-
established protocols to direct the diﬀerentiation of these cell
lines into cardiomyocytes. They tried to eliminate the eﬀect of
the diﬀerences in genetic background between the cells through
three independent approaches:
- shRNA-mediated knockdown of TAZ in primary rat
cardiomyocytes, to conﬁrm the metabolic phenotype in
primary cells from another species.
- Phenotypic rescue in BTHS hiPSC-CMs, by transfection with
a synthetic modiﬁed RNA encoding wild-type tafazzin (Wang
et al., 2014b).
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FIGURE 8 | Future role of iPSC-CMs in the clinical care of patients with hereditary cardiac disorders. iPSC-CMs can be profiled by molecular
techniques, and electrical and mechanical measurements, and on the basis of their response to various pharmacological agents. Such studies can provide
information about the predicted severity of disease, associated risks, and response to therapy, which can be used to support clinical decision making. In
addition, the functional characterization of the tissue might help to identify candidate causal variants and to facilitate the screening of family members for the
disease. Abbreviations: iPSCs, induced pluripotent stem cells; iPSC-CMs, induced pluripotent stem cell-derived cardiomyocytes; PMBCs, peripheral blood
mononuclear cells.
- Cas9-mediated genome editing (Mali et al., 2013; Byrne et al.,
2014) to introduce TAZmutations into isogenic control hiPSC
lines (Figure 9).
Wang et al. (2014a) then performed rigorous experiments
on the patient-derived and genetically engineered iPSC cells
by sarcomeric reconstitution and biophysical testing to assess
the causal role of TAZ mutations in cardiac dysfunction
associated with BTHS. This approach yielded highly impressive
results including an ex vivo conﬁrmation of structural and
functional abnormalities linked to TAZ mutation, which ended
in sparse and irregular sarcomeres with reduced mechanical
capabilities.,
It is clear that by using patient-speciﬁc iPSC lines it is possible
to obtain new mechanistic insights into the physiopathology of
a mitochondrial CM associated with a single gene mutation and
potential strategies for its treatment.
USING iPSC TECHNOLOGY TO STUDY
SARCOMEROGENESIS
The diﬀerentiation of disease-relevant and patient-speciﬁc iPSCs
into relevant cell types as described above now makes it
possible to develop appropriate cell-based assays for assessing
relevant aspects of the disease studied (Figure 9). Dudek
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FIGURE 9 | Induced pluripotent stem cells generated from patients suffering from Barth syndrome. Disease-specific mutations are introduced into
wild-type iPSC lines, facilitating direct comparison with isogenic controls. iPSC-CMs are subjected to biochemical analyses, such as phospholipid analysis by mass
spectrometry and mitochondrial structure/function analysis. iPSC-CMs are also used in “heart-on-chip” assays, to model the pathophysiology of the disease in vitro
and to investigate the underlying mechanism of BTHS (particularly as concerns binding capacity or force characteristics during contraction) and to evaluate potential
therapies involving untargeted or targeted antioxidants. [This figure was developed from a publication of Wang et al. (2014b) and from comments recently published
concerning the missing link between mitochondrial ROS production and the destabilization of sarcomere organization, raising questions about the relationship
between ROS and dilated LVNC in BTHS patients (Raval and Kamp, 2014; Zweigerdt et al., 2014)].
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et al. (2013) reported aberrant RC function in undiﬀerentiated
iPSCs obtained from three BTHS patients (derived from dermal
ﬁbroblasts) with diﬀerent TAZ mutations - TAZ10, 590 G > T
missense, severe BTHS; TAZ13, 110-1 AG > AC splice site,
severe BTHS; TAZ15, 170G > T missense, mild BTHS. The
diagnosis was based on analyses of the CL/MLCL ratio in
the patients’ ﬁbroblasts. BTHS-iPSCs reproduced the tafazzin
deﬁciency on CL remodeling and mitochondrial defects in
oxidative phosphorylation. These cells had a very low basal
oxygen consumption rate but maximal respiratory capacity and
this was accompanied by major changes in the structure of
the RC supercomplexes, resulting in a massive increase in ROS
production. Supercomplex disassembly, dysregulated respiration
with aberrant ROS production (Gonzalvez et al., 2013) and
respiration and mitochondrial deﬁciencies (Xu et al., 2005;
Gonzalvez et al., 2013) have also been described in patient-
derived BTHS lymphoblasts.
In contrast to the above results, Wang et al. (2014a) reported
that the mitochondria in BTHS-hiPSC-CMs were smaller and
more fragmented displaying elevated basal oxygen consumption
rate with an impaired electron transport. The discrepancy
between the ﬁndings (Dudek et al., 2013) and those of Wang
et al. (2014a) highlights the need to investigate the eﬀects of
disease-speciﬁc mutations carefully and precisely, not only in
the particular cell type studied (presumed to show the disease
phenotype), but also in undiﬀerentiated cells or, even other
diﬀerentiated derivatives, to delineate the tissue-speciﬁc eﬀects,
which may include phenotypic heterogeneity due to diﬀerent
mutations (Figure 10).
Mitochondria regulate cardiomyocyte diﬀerentiation (Hom
et al., 2011), which involves the assembly of organized arrays
of sarcomeres. BTHS-derived hiPSC-CM sarcomeres grown
on an unpatterned gelatin substrate form much less regular
assemblies than control hiPSC-CMs (Figure 10). The lack of a
robust pipeline of therapeutic agents for treating heart disease
is partly due to the lack of in vitro models reproducing the
essential structure-function relationships of healthy and diseased
myocardia. One up-to-date approach was to plate individual
hiPSC-CMs onto micropatterned ﬁbronectin rectangles designed
tomimic the dimensions of human adult cardiomyocytes (Gerdes
FIGURE 10 | Pathophysiology of Barth syndrome and iPSC-CMs. Healthy iPSC-CMs have organized myofilaments and mitochondria with active transacylase
tafazzin linked to the outer membrane and facing the intermembrane space (Brandner et al., 2005), with tafazzin in an intermembrane position (Herndon et al., 2013),
allowing CL processing. This results in the conversion of monolysocardiolipin (MLCL; immature CL) to L4-CL (mature CL) in the IMM and the formation of normal
electron transport chain (ETC) complexes and normal ATP synthase function. However, the ETC normally produces few superoxide anions in a process
homeostatically controlled by endogenous mitochondrial antioxidant (e.g., MnSOD). By contrast, in BTHS, iPSC-CMs with mutant TAZ lack L4-CL. CL cannot be
processed correctly and respiratory complexes do not form normally (as they have a lower compaction) resulting in ETC complex malfunction and abnormally high
levels of ROS production (red circle), contributing to myofilament disarray and contractile dysfunction. By contrast, when the defect is complemented, the respiratory
supercomplexes are at the right distance, compacted and superoxide ion production is low (dashed black circle) (Claypool et al., 2008). modRNA encoding tafazzin
can rescue the disease phenotype, as can buffering mitochondrial ROS with mitoTEMPO or providing a precursor for L4-CL, linoleic acid (redrawn from Raval and
Kamp, 2014).
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and Capasso, 1995) to develop a “heart-on-chip” (HOC) in
which sarcomeres self-organize into a laminar myocardium.
The resulting mimetic contractile muscular thin ﬁlm (MTF)
constructs are able to contract and curl (Grosberg et al.,
2011, 2012). With this technique, cyclic stretching could be
observed to activate gene expression proﬁles characteristic of
pathological remodeling (with a decrease in α- to β-myosin
heavy chain ratios for example) and induce maladaptive changes
to myocyte shape and sarcomere alignment (McCain et al.,
2013). The sarcomeres in the control iPSC-CMs initially extended
serially along the entire length of the cell, whereas those in
BTHS-iPSC-CMs were intermittent and sparse (Figure 10). In
mechanical investigations based on this system, hiPSC-CMs from
patient-derived cell lines had weaker contractile functions, while
treatment with TAZ modRNA restored sarcomere regularity.
Culture in glucose normalized ATP levels to an extent similar
to that achieved with TAZ modRNA, but did not rescue
sarcomere formation. These results are particularly interesting,
given that lymphoblasts derived from BTHS patients display
slightly higher levels of ATP production via glycolysis (i.e., in
the presence of glucose) than control lymphoblasts, suggesting
that the impairment of mitochondrial ATP production may
be compensated temporarily by an increase in the size of the
mitochondrial compartment (Gonzalvez et al., 2013). Combined
with the sarcomere data, these later observations suggest
that sarcomerogenesis is sensitive to mitochondrial function
(especially during stem cells diﬀerentiation), regardless of whole-
cell ATP levels (Chung et al., 2007).
It would be of interest to perform electrophysiological
analyses to determine whether the observed TAZ mutation-
dependent phenotypes result in impaired electromechanical
coupling. Impaired coupling may underlie additional clinical
signs in BTHS, such as ventricular arrhythmia and sudden
cardiac death (Zweigerdt et al., 2014).
THERAPEUTIC STRATEGIES
Wang et al. (2014a) used their BTHS-hiPSC-CMs disease model
to test potential therapeutic strategies for BTHS. Valianpour
et al. (2003) reported that ﬁbroblasts from both BTHS patients
and normal controls incubated with diﬀerent concentrations
of linoleic acid (a major CL precursor and an antioxidant)
displayed dose- and time-dependent increases in CL levels. This
was interpreted as evidence that increasing the amount of linoleic
acid in the diet might be beneﬁcial for patients with BTHS.Wang
et al. (2014a) found that linoleic acid could rescue the defect in
the organization and biophysical characteristics of sarcomeres.
Moreover, using an antioxidant targeted to mitochondria,
Mito TEMPO, they achieved a similar reorganization of the
sarcomeres and rescue of function (Figure 10). Advances in
mitochondrial research over the last decade have focused on the
preservation of mitochondrial function, which is essential for
cellular energy production, in the myocardium. Experimental
and clinical trials have been conducted with various molecules
targeted to the mitochondria, including MnSOD mimetics,
such as EUK-8, EUK-134 and MitoSOD; choline esters of
TABLE 3 | Antioxidants targeted to mitochondria.
Antioxidant Generic name
TEMPOL
EUK-8, EUK-134
Salen
Glutathione
NAC
Vit. E
4-hydroxy-2,2,6,6,tetramethylpiperidine-N-oxide
Salen derivative – inoganic MnSOD mimetics
Salen derivative – Mn(III) complex o-vanillin
Choline ester of glutathione
N-acetyl-1-cysteine
Vitamin E
Mitochondrially targeting with tetraphenylphosphonium (TPP+ )
MitoTEMPO (TPP+-1-hydroxy-3-carboxy-pyrrolidine)
MitoQ10 (TPP+-Quinone10)
Lipoic acid
SKQ1, (TPP+-plastoquinone)
MitoSOD, MnSOD
Szeto-Schiller or SS-peptides (SS-02, SS-31)
glutathione and N-acetyl-L-cysteine; triphenylphosphonium-
ligated vitamin E, lipoic acid, plastoquinone and mitoCoQ10;
and Szeto-Schiller (SS)-peptides (SS-02 and SS-31) (Table 3).
Many of the results obtained have been inconclusive, but some,
particularly those relating to mitoQ10 (very similar to the
MitoTEMPO used by Wang’s team work) (Ajith and Jayakumar,
2014) have been informative in the sense that they point
out the essential role of ROS. It may not be straightforward
to translate these small-molecule interventions into patient
treatment, even though related compounds are currently being
tested in clinical trials [MitoQ for Parkinson disease, non-
alcoholic fatty liver disease (NAFLD) and high levels of liver
enzymes due to hepatitis C; SKQ1 for dry eye syndrome] (Table 3;
Figure 11).
Taken together, these results provide an intriguing link
between impaired sarcomere organization (and weak force
generation) in cardiomyocytes and high levels of ROS production
associated with the mitochondrial dysfunctions observed in
cells with TAZ gene mutations. This is not particularly
surprising, because ROS have been implicated in cardiomyocyte
diﬀerentiation, sarcomerogenesis, and contractility (Chung et al.,
2007; Hom et al., 2011; Steinberg, 2013).
PERSPECTIVES
Despite major progress in our understanding of BTHS, there
are still key unanswered questions to be addressed, over and
above the potentially large diﬀerences between any two patient
mutations studied. In particular, cells carrying similar mutations
may display diﬀerent patterns of contractile dysfunction in the
“heart-on-chip” assay. Further clinical information is required
concerning the features of the disease in the patients sampled.
Moreover, current methods of iPSC generation mostly produce
CMs with embryonic heart features, such as their dependence
on glycolysis. It is unclear how relevant results obtained with
embryonic-like CMs are to disease in adult hearts (Figure 8).
Questions also remain as to whether the disease begins in and
is limited to the mitochondria, or whether there are other
functional impacts, on other compartments within cells, such as
Frontiers in Genetics | www.frontiersin.org 18 January 2016 | Volume 6 | Article 359
Saric et al. Barth Syndrome Breaking News
FIGURE 11 | Rationale for the accumulation of MitoQ10 or SKQ1 in cells and mitochondria. The antioxidant component of MitoQ10 is the same ubiquinone
found in coenzyme Q10 (Kelso et al., 2001), whereas the antioxidant of SKQ1 is a plastoquinone (Antonenko et al., 2008). Within mitochondria, the ubiquinone part
of MitoQ is rapidly activated to yield the active ubiquinol antioxidant by the enzyme complex II (also called succinate dehydrogenase) in the mitochondrial respiratory
chain (RC). As a result of detoxifying a free radical or other ROS, the ubiquinol part of MitoQ is converted to a ubiquinone, which is then recycled back to the active
antioxidant by complex II within the mitochondria (James et al., 2005). It is this combination of a 1000-fold concentration within mitochondria, with conversion to the
active antioxidant and recycling back to the active antioxidant after the detoxification of a free radical that makes MitoQ an effective mitochondrion-targeted
antioxidant.
the ER or peroxisomes (Raja and Greenberg, 2014), which also
contain CLs.
Tafazzin appears to be necessary for the execution of
mitophagy (Hsu et al., 2015) and this observation may help to
add some new directions to BTHS research, since an inhibition
of mitophagy may lead to the accumulation of unwanted
deleterious mitochondria in the patients’ tissues. Tafazzin is
speciﬁcally required for the initiation of mitophagy whereas
tafazzin depletion does not impair other autophagic processes.
However, how does tafazzin regulate the initiation of mitophagy?
One possible explanation was provided by Chu et al. (2013),
who showed that externalization of CL from the IMM to
the OMM surface serves as a recognition signal that directs
damaged mitochondria to mitophagy (Chu et al., 2013, 2014).
Indeed, the association between impaired mitochondrially driven
apoptosis (Gonzalvez et al., 2008, 2013) and the inhibition of
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FIGURE 12 | Cardiolipin and the main transduction pathways for apoptosis and autophagy. Collapse of cardiolipin content allows movements of CL from
the inner mitochondrial membrane to the outer membrane required for both mitochondrially driven apoptosis and autophagic processes. If cardiolipin peroxidation is
a prerequisite for the release of pro-apoptotic factors from the mitochondria into the cytosol, it could be problematic for mitophagy homeostasis. Moreover, changes
in acyl chain composition associated with TAZ gene mutation and tafazzin dysfunction are directly involved in the inhibition of mitochondrially driven apoptosis
(Gonzalvez et al., 2008, 2013) but has also be implicated in the possible inhibition of the mitophagic processes (Hsu et al., 2015). LC3-II is localized to
preautophagosomes and autophagosomes, making this protein an autophagosomal marker (Kabeya et al., 2000) but also a marker of more specific
mitophagosomes (that perform a specific type of autophagy called mitophagy). Normal and mutated tafazzin are represented by yellow and red stars, respectively,
IMM, inner mitochondrial membrane; IMS, intermembrane space; OMM, outer mitochondrial membrane, LC3-II,microtubule-associated protein 1 light chain 3-II).
A black cross marks the abolition of protein-to-protein interactions.
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mitophagy (Hsu et al., 2015) due to TAZ mutation, CL non-
maturation (Figure 12) and related ROS production is strictly
linked to LVNC (Figure 1). Failure to maintain a critical balance
betweenmitophagy andmitochondrial biogenesis or homeostatic
turnover of mitochondria results in a population of dysfunctional
mitochondria (and, in the case of BTHS, with immature CL
and MLCL accumulation) that contribute to various disease
processes. Inhibition of autophagy is emerging as a main actor
together with apoptosis defects leading to LVNC.
Large mitochondrial DNA deletions, a common cause of
mitochondrial diseases, have been detected in pluripotent stem
cells (Van Haute et al., 2013) and during aging processes (Bratic
and Larsson, 2013). An additional strategy is open to researchers,
because the targeted engineering of the mitochondrial genome of
iPSCs is now possible (Bacman et al., 2013). This makes it possible
not only to model mitochondrial diseases in cell culture, but also
to investigate the eﬀects of the age-related or reprogramming-
associated accumulation of heteroplasmic mutations in iPSCs.
Such studies will provide answers to an important medical
question, which is also highly relevant to BTHS: Are the iPSCs
generated from older individuals of similar biological quality
as those generated from younger cell sources, such as cord
blood, or should the banking of primary cells be initiated at
the neonatal stage, for the subsequent generation of clinically
available, applicable products.
Mutations causing abnormalities of mitochondrial function
and mtDNA are associated with common cardiac diseases,
such as BTHS. Despite the promising mitochondria-targeted
drugs, currently used at the cellular or tissue levels and
emerging from the laboratory, very few such molecules
have successfully completed clinical trials. Antioxidants ligated
to tetraphenylphosphonium, such as vitamin E, lipoic acid,
plastoquinone, MnSOD, and mitochondrial CoQ10, have been
experimentally shown to be eﬀective for attenuating the
mitochondrial oxidative stress associated with such diseases.
MitoQ10, which targets mitochondria, could provide a novel
approach to decreasing oxidative damage and has the potential
to become a new therapeutic agent for use in humans. These
strategies suggest that the pharmacological restoration of a
normal or upregulated mitophagy could provide a novel additive
treatment of the pathology. However, currently there is too little
evidence from randomized trials to advance a recommendation
for systematic use of antioxidant supplementation to prevent
heart disease. As mitochondrial damage is a key element
of the pathophysiology of heart disease in general, various
approaches based on the targeting of antioxidant compounds to
mitochondria should be explored, for the development of new
treatments for cardiomyopathies linked to BTHS.
CONCLUSION
There has been a substantial improvement of our understanding
of the molecular mechanisms underlying the BTHS pathology
and there is an increasing hope for future eﬃcient therapeutic
treatments. However, many additional studies will be required
before mitochondria-targeted treatments can be made available
for the prevention and treatment of diverse cardiomyopathies.
Such basic work will help us understand the disease mechanism
and its numerous phenotypes.
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